- Organizations: RevOpsis Therapeutics
Pipeline
Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization
Exclusive licensing agreement also extends up to four retinal biologics.Pipeline
RevOpsis receives NEI grant for advancing retinal vascular disease candidate
The $1.8M funding will support clinical development of RO-104, a fully human modular tri-specific biologic targeting three angiogenic pathways for wet AMD.Pipeline